Skip to main content

Table 2 Summary of treatments

From: Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial

Items   TOCE TOCE + HAIC Provability
95%CI
n = 9 n = 10
Number of Treatment Session (1/2/3/4/5/6/7/8) 6/1/1/1/0/0/0/0 3/1/1/1/2/1/0/1 0.057
Total 15 36
Median 1 3.5
Range 1–4 1–8
Interval between Sessions (day) Median 94.5 90.5 0.96
Range 56–259 48–518
DDP-H (mg/body) Median N/A 80 N/A
Range N/A 40–100
Miriplatin (mg/body) Median 62 62 0.99
Range 40–120 16–120
anti-tumor Effecta CR 0 (0) 6 (3) 0.0025
PR 0 (0) 7 (2)
SD 6 (3) 15 (5)
PD 9 (9) 8 (8)
Not evaluable 0 0
DCR (%) 40.0 77.8
Disease Progression (day) Median 91 423 0.025
Range 29–322 34–1243 1.17–10.86
Overall Survival (day) Median 706 733 0.40
Range 62–1176 384–1827 0.54–4.54
  1. a anti-tumor effect was evaluated based on the modified Response Evaluation Criteria In Solid Tumors guideline. CR complete response, PR partial response, SD stable disease, PD progressive disease, DCR disease control rate, HR hazard ratio, TOCE transarterial oily chemoembolization, TACE transarterial chemoembolization, HAIC hepatic arterial infusion chemotherapy